�The estimated rate of anaphylaxis in young women after human papillomavirus (HPV) vaccination was significantly higher - 5 to 20 fold - than that identified in comparable school-based vaccination programs, according to a study published in CMAJ hypertext transfer protocol://www.cmaj.ca/press/179_6_525.pdf. However, the overall rates of anaphylaxis were broken with no associated good lasting effects.
In a subject field of 114,000 women, a squad of Australian researchers found 12 suspected of anaphylaxis, and confirmed 8 of these, in a 2007 vaccination programme in New South Wales, Australia. Symptoms included difficulty breathing, sickness and rashes.
Dr. Julia Brotherton and colleagues postulate that reasons for an increased rate of anaphylaxis crataegus oxycantha include possible allergic reaction to the vaccine components, enhanced adverse event surveillance, higher rates of anaphylaxis in women from midadolescence compared with men, and an ostensible increase in incidence of anaphylaxis in Australia.
The estimated rate of anaphylaxis following HPV vaccination was 2.6 per 100,000 doses administered compared with a pace 0.1 per 100 000 doses administered in a 2003 school-based meningococcal C inoculation program.
HPV vaccination programs will begin this fall in the United Kingdom and other European countries as well as in parts of Canada and the United States.
Dr. Brotherton stresses "the importance of good training for staff administering vaccines in school or other settings in the recognition and management of suspected anaphylaxis and its reporting." They conclude that anaphylaxis following the HPV vaccine is rare and vaccine programs should continue.
Anaphylaxis is a rare but serious contrary event and highlights the importance of vaccine safety studies later vaccine licensing and careful management of reactions in immunization clinics, says Dr. Neal Halsey, Institute of Vaccine Safety, Johns Hopkins Bloomberg School of Public Health in a related commentary hTTP://www.cmaj.ca/press/179_6_509.pdf. He states "before concluding that the HPV vaccine is associated with higher rates of anaphylaxis than other vaccines everywhere, cases in other populations should be reviewed�.As of July 21, 2008, 11 cases have been reported [in the US] in 2008. Over 13 million doses of this vaccine get been distributed as of the end of 2007."
A CMAJ editorial http://www.cmaj.ca/press/179_6_503.pdf states that this study indicates the HPV vaccine is "remarkably safe." The field of study provides an excellent opportunity for Canada's public wellness community "to restart world discussions around the rubber of the HPV vaccine, the precautions taken to mitigate risks if anaphylaxis occurs, and the precaution taken in surveillance for adverse events following vaccination," write Drs. Noni MacDonald, Matthew Stanbrook and Paul Hebert.
Source: Kim Barnhardt
Canadian Medical Association Journal
More info
